Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Medical Technology
  • Guardant wins FDA nod for diagnostic guiding use of AstraZeneca’s Etcamah

Guardant wins FDA nod for diagnostic guiding use of AstraZeneca’s Etcamah

September 7, 2026Posted inMedical Technology

Hot on the heels of the approval for AstraZeneca’s breast cancer drug Etcamah, Guardant Health has been given the green light for its companion diagnostic.

Post navigation

Previous Post
nikkei-225-firms-face-flood-risks-across-industries-and-regions Nikkei 225 firms face flood risks across industries and regions
Next Post
Boston Scientific cyberattack likely to have ‘material impact’ on financial results

Recent Posts

  • Silicon’s complex effects on arsenic in rice shaped by terrain and soil
  • Cobimetinib boosts calreticulin and reshapes immunity in triple-negative breast cancer
  • Dual radioligand therapy targets neuroendocrine bone metastases in pilot study
  • VMA21 loss disrupts autophagy and vesicle trafficking in X-linked myopathy
  • X-ray fluorescence mapping and quantification of metal(loid)s in animal samples

Archives

  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • March 2024
  • January 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top